SCHEMBL6421048

SCHEMBL6421048

C(=N/Nc1nc2nonc2nc1Nc1ccccc1)\c1ccco1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.49
MAPT P10636 7/20 0.49
KMT2A Q03164 7/20 0.49
MEN1 O00255 6/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.46
TDP1 Q9NUW8 3/20 0.46
MAOB P27338 2/20 0.46
MAOA P21397 1/20 0.46
PKM P14618 1/20 0.46
NPC1 O15118 7/20 0.46
RAB9A P51151 6/20 0.46
KDM4E B2RXH2 4/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3055383 1.00 GAA (0.49) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL6420784 0.90 MAPT (0.48) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL6417007 0.90 MAPT (0.51) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL6417000 0.90 MAPT (0.51) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL6508259 0.90 MAPT (0.48) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL6431993 0.87 SMN1; SMN2 (0.51) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL6431990 0.87 SMN1; SMN2 (0.51) GAAMAPTKMT2AMEN1L3MBTL1
SCHEMBL3058317 0.87 SMN1; SMN2 (0.48) GAAMAPTKMT2AMEN1NPSR1
SCHEMBL3058312 0.87 SMN1; SMN2 (0.48) GAAMAPTKMT2AMEN1NPSR1
SCHEMBL6414713 0.84 SMN1; SMN2 (0.50) GAAMAPTKMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 GAA 3186/4885MAPT 4420/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.